At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 27 enrolled
Drug / intervention
Comparator: placebo +1 moredrug
Likely dose
Comparator: Estrace 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Effects of Estrogen on Estrogen Receptor Biomarkers in Healthy Postmenopausal Women
In Brief
A Phase 1 clinical trial evaluating Comparator: placebo and Comparator: Estrace for Postmenopause. Completed, enrolled 27 participants.
Detailed Summary
This study will develop a model for the assessment of successful activation/engagement of estrogen receptor beta using salivary biomarkers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostmenopause
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2008
Primary CompletionOct 2008
First PostedDec 2008
TodayJul 2026
First PostedDec 1, 2008
Enrollment StartMay 1, 2008
Primary CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 17.6 years ago
Interventions
Comparator: placebodrug
placebo capsule once daily for 7 days.
Comparator: Estracedrug
Estrace 0.5 mg or 2 mg tablets once daily for 7 days.